From man to mouse: The Mptp model of parkinson disease

Movement Disorders

Volumn , Issue , 2005, Pages 149-160

  Jackson Lewis, Vernice ^a   Jay Smeyne, Richard ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646592921     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088382-0/50012-8     Document Type: Chapter

References (171)

1. Ara J., Przedborski S., Naini A.B., Jackson-Lewis V., Trifiletti R.R., Horwitz J., Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 1998, 95:7659-7663.
2. Aulak K.S., Miyagi M., Yan L., West K.A., Massillon D., Crabb J.W., Stuehr D.J. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci U S A 2001, 98:12056-12061.
3. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991:120-131.
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
5. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999, 155:268-273.
6. Brecknell J.E., Dunnett S.B., Fawcett J.W. A quantitative study of cell death in the substantia nigra following a mechanical lesion of the medial forebrain bundle. Neurosci 1995, 64:219-227.
7. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999, 823:1-10.
8. Brooks W.J., Jarvis M.F., Wagner G.C. Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 1989, 76:1-12.
9. Burns R.S., LeWitt P., Ebert M.H., Pakkenberg H., Kopin I.J. The clinical syndrome of striatal dopamine deficiency; parkinsonism induced by MPTP. N Engl J Med 1985, 312:1418-1421.
10. Cassina A.M., Hodara R., Souza J.M., Thomson L., Castro L., Ischiropoulos H., Freeman B.A., Radi R. Cytochrome c nitration by peroxynitrite. J Biol. Chem 2000, 275:21409-21415.
11. Cerruti C., Walther D.M., Kuhar M.J., Uhl G.R. Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Mol Brain Res 1993, 18:181-186.
12. Cheng F.C., Ni D.R., Wu M.C., Kuo J.S., Chia L.G. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice. Neurosci Lett 1998, 252:87-90.
13. Chun H.S., Gibson G.E., DeGiorgio L.A., Zhang H., Kidd V.J., Son J.H. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 2001, 76:1010-1021.
14. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992, 58:786-789.
15. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998, 4:1318-1320.
16. Cook R., Lu L., Gu J., Williams R.W., Smeyne R.J. Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice. Mol Brain Res 2003, 110:279-288.
17. D'Amato R.J., Lipman Z.P., Snyder S.H. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+binds to neuromelanin. Science 1986, 231:987-989.
18. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
19. Date I., Aoi M., Tomita S., Collins F., Ohmoto T. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. Neuroreport 1998, 9:2365-2369.
20. Daubner S.C., Lohse D.L., Fitzpatrick P.F. Expression and characterization of catalytic and regulatory domains of rat tyrosine hydroxylase. Protein Sci 1993, 2:1452-1460.
21. de Rijk M.C., Breteler M.M., Graveland G.A., Ott A., Grobbee D.E., van der Meche F.G., Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995, 45:2143-2146.
22. Del Zompo M., Piccardi M.P., Ruiu S., Quartu M., Gessa G.L., Vaccari A. Selective MPP+uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J Pharm 1993, 109:411-414.
23. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
24. Di Monte D., Sandy M.S., Ekstrom G., Smith M.T. Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem Biophys Res Commun 1986, 137:303-309.
25. Di Monte D.A., Royland J.E., Irwin I., Langston J.W. Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology 1996, 17:697-703.
26. Di Monte D.A., Wu E.Y., Irwin I., Delanney L.E., Langston J.W. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia 1992, 5:48-55.
27. Dringen R., Pfeiffer B., Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 1999, 19:562-569.
28. Drukarch B., Schepens E., Stoof J.C., Langeveld C.H., Van Muiswinkel F.L. Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species. Free Rad Biol Med 1998, 25:217-220.
29. Duvoisin R.C. Genetic and environmental factors in Parkinson's disease. Adv Neurology 1999, 80:161-163.
30. Elbirt K.K., Bonkovsky H.L. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians 1999, 111:438-447.
31. Fahn S., Przedborski S. Parkinsonism. Merritt's Neurology 2000, 679-693. Lippincott Williams and Wilkins, Philadelphia. 10th Edition. L.P. Rowland (Ed.).
32. Faull R.L., Mehler W.R. The cells of origin of nigrotectal, nigrothalamic and nigrostriatal projections in the rat. Neuroscience 1978, 3:989-1002.
33. Fernandez-Gonzales A., Perez-Otano I., Morgan J.I. MPTP selectively induces heme oxygenase-1 expression in striatal astrocytes. Eur J Neurosci 2000, 12:1573-1583.
34. Fornai F., Battaglia G., Gesi M., Giorgi F.S., Orzi F., Nicoletti F., Ruggieri S. Time-course and dose-response study on the effects of chronic L-dopa administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res 2000, 887:110-117.
35. Formo L.S., DeLanney L.E., Irwin I., Monte D.Di, Langston J.W. Astrocytes and Parkinson's disease. Prog Brain Res 1992, 94:429-436.
36. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USS A 1994, 91:5104-5108.
37. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69:1322-1325.
38. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 1998, 70:1973-1978.
39. Gasser T. Genetics of Parkinson's disease. J Neurol 2001, 248:833-840.
40. German D.C., Manaye K., Smith W.K., Woodward D.J., Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989, 26:507-514.
41. Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., Lee V.M. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 2000, 59:528-533.
42. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
43. Gong L., Wyatt R.J., Baker I., Masserano J.M. Brain-derived and glial cell line-derived neurotrophic factors protect a catecholaminergic cell line from dopamine-induced cell death. Neurosci Lett 1999, 263:153-156.
44. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
45. Grofova I. Extrinsic connections of the neostriatum. The Neostriatum 1979, 37-51. Pergamon Press, Oxford. I. Divac, R.G.E. Oberg (Eds.).
46. Hadjiconstantinou M., Fitkin J.G., Dalia A., Neff N.H. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J Neurochem 1991, 57:479-482.
47. Hamre K., Tharp R., Poon K., Xiong X., Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 1999, 828:91-103.
48. Hansen T.W. Bilirubin in the brain. Distribution and effects on neurophysiological and neurochemical processes. Clin Pediatr (Phila) 1994, 33:452-459.
49. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
50. Hatakeyama S., Hayasaki Y., Masuda M., Kazusaka A., Fujita S. Mechanism for mouse strain differences in the protective effect of Sudan III against the in vivo genotoxicity of 7,12-dimethyl-benz[a]anthracene. Tox Lett 1996, 89:231-239.
51. Hazell A.S., Itzhak Y., Liu H., Norenberg M.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 1997, 68:2216-2219.
52. Heaton M.B., Paiva M., Madorsky I., Mayer J., Moore D.B. Effects of ethanol on neurotrophic factors, apoptosis-related proteins, endogenous antioxidants, and reactive oxygen species in neonatal striatum: relationship to periods of vulnerability. Dev Brain Res 2003, 140:237-252.
53. Higuchi S., Muramatsu T., Arai H., Hayashida M., Sasaki H., Trojanowski J.Q. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transn 1995, 10:107-113.
54. Hirrlinger J., Schulz J.B., Dringen R. Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. J Neurochem 2002, 82:458-467.
55. Hirsch E.C., Hunot S. Nitric oxide, glial cells and neuronal degeneration in parkinsonism. TIPS 2000, 21:163-165.
56. Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann Neurol 1998, 44:S115-S120.
57. Hirsch E.C., Hoglinger G., Rousselet E., Breidert T., Parain K., Feger J., Ruberg M., Prigent A., Cohen-Salmon C., Launay J.M. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm 2003, Suppl:89-100.
58. Hu C.J., Sung S.M., Liu H., Chang J.G. No mutation of G209A in the alpha-synuclein gene in sporadic Parkinson's disease among Taiwan Chinese. Eur Neurol 1999, 41:85-87.
59. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996, 72:355-363.
60. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999, 19:3440-3447.
61. Inazu M., Takeda H., Matsumiya T. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem 2003, 84:43-52.
62. Ischiropoulos H., al-Mehdi A.B. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995, 364:279-282.
63. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
64. Jellinger K.A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 1999, 14:115-140.
65. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 2003, 9:131-137.
66. Kalaria R.N., Mitchell M.J., Harik S.I. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc Natl Acad Sci U S A 1987, 84:3521-3525.
67. Khan F.H., Sen T., Chakrabarti S. Dopamine oxidation products inhibit Na+, K+-ATPase activity in crude synaptosomal-mitochondrial fraction from rat brain. Free Radic Res 2003, 37:597-601.
68. Kirschner P.B., Jenkins B.G., Schulz J.B., Finkelstein S.P., Matthews R.T., Rosen B.R., Beal M.F. NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Res 1996, 713:178-185.
69. Kitayama S., Wang J.B., Uhl G.R. Dopamine transporter mutants selectively enhance MPP+ transport. Synapse 1993, 15:58-62.
70. Klivenyi P., Clair D.ST, Wermer M., Yen H.C., Oberley T., Yang L., Beal M.Flint Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol Dis 1998, 5:253-258.
71. Kopin I.J. Features of the dopaminergic neurotoxin MPTP. Ann NY Acad Sci 1992, 648:96-104.
72. Kopin I.J., Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 1988, 11:81-96.
73. Lancaster J.R. Diffusion of free nitric oxide. Methods Enzymol 1996, 268:31-50.
74. Lander E.S., Schork N.J. Genetic dissection of complex traits. Science 1994, 265:2037-2048.
75. Langston J.W. The case of the tainted heroin. The Sciences 1985, 25:34-40.
76. Largston J.W., Palfreman J. The Case of the Frozen Addicts 1996, Vintage Books, New York.
77. Lau Y.S., Fung Y.K., Trobough K.L., Cashman J.R., Wilson J.A. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurotoxicology 1991, 12:189-199.
78. LaVoie M.J., Hastings T.G. Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J Neurochem 1999, 73:2546-2554.
79. Le Couteur D.G., Leighton P.W., McCann S.J., Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Movement Dis 1997, 12:760-763.
80. Levine M.S., Hull C.D., Fisher R.S., Buchwald N.A., Heller A. Effects of neonatal destruction of the medial forebrain bundle in the cat: long-term neurochemical, locomotor, and regulatory deficits. Exp Neurol 1983, 81:340-358.
81. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
82. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., Brecha N., Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
83. MacMillan-Crow L.A., Crow J.P., Kerby J.D., Beckman J.S., Thompson J.A. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A 1996, 93:11853-11858.
84. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997, 37:517-554.
85. Maines M.D. The heme oxygenase system and its functions in the brain. Cell Mol Biol (Noisy-le-grand) 2000, 46:573-585.
86. Marini A.M., Lipsky R.H., Schwartz J.P., Kopin I.J. Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. J Neurochem 1992, 58:1250-1258.
87. McGeer P.L., McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alz Dis Assoc Dis 1998, 12(Suppl 2):S1-S6.
88. McNaught K.S., Thull U., Carrupt P.A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. Biochem Pharmacol 1996, 51:1503-1511.
89. McNaught K.S.P., Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridium and 6-hydroxydopamine induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 1999, 73:2469-2476.
90. Melamed E., Offen D., Shirvan A., Ziv I. Levodopa-an exotoxin or a therapeutic drug?. J Neurol 2000, 247(Suppl 2):II135-II139.
91. Miller G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporters and neuronal injury. TIPS 1999, 20:424-429.
92. Miller G.W., Erickson J.D., Perez J.T., Penland S.N., Mash D.C., Rye D.B., Levey A.I. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999, 156:138-148.
93. Mitra N., Mohanakumar K.P., Ganguly D.K. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. J Neurochem 1994, 62:1906-1912.
94. Mizuno Y., Sone N., Suzuki K., Saitoh T. Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J Neurol Sci 1988, 86:97-110.
95. Mizuno Y., Sone N., Suzuki K., Saitoh T. Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J Neurol Sci 1988, 86:97-110.
96. Muller T., Buttner T., Gholipour A.F., Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003, 341:201-204.
97. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M., Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol 1994, 126:195-204.
98. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm 2000, Suppl:277-290.
99. Nakajima K., Hida H., Shimano Y., Fujimoto I., Hashitani T., Kumazaki M., Sakurai T., Nishino H. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res 2001, 916:76-84.
100. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985, 36:2503-2508.
101. Nicklas W.J., Youngster S.K., Kindt M.V., Heikkila R.E. MPTP, MPP+ and mitochondrial function. Life Sci 1987, 40:721-729.
102. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., Rinne J.O. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001, 16:608-615.
103. Nussbaum R.L., Polymeropoulos M.H. Genetics of Parkinson's disease. Hum Mol Gen 1997, 6:1687-1692.
104. O'Banion M.K. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 1999, 8:1521-1536.
105. Ofori S., Schorderet M. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopamine synthesis and release in the rabbit retina in vitro. Neuropharm 1987, 26:1607-1610.
106. Olney J.W., Zorumski C.F., Stewart G.R., Price M.T., Wang G.J., Labruyere J. Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases. Exp Neurol 1990, 108:269-272.
107. Otto D., Unsicker K. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells. Glia 1994, 11:47-56.
108. Parkinson J. An essay on shaking palsy 1817, Sherwood, Neeley and Jones, London.
109. Payami H., Zareparsi S. Genetic epidemiology of Parkinson's disease. J Ger Psych Neurol 1998, 11:98-106.
110. Petersen A.A., Larsen K.E., Behr G.G., Romero N., Przedborski S., Brundin P., Sulzer D. Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res Bull 2001, 56:331-335.
111. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
112. Poss K.D., Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci U S A 1997, 94:10919-10924.
113. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998, 13(Suppl 1):35-38.
114. Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2003, 991:189-198.
115. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996, 93:4565-4571.
116. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., Almer G. The parkinsonian toxin MPTP: action and mechanism. Rest Neurol Neurosci 2000, 16:135-142.
117. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992, 12:1658-1667.
118. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 2001, 76:637-640.
119. Quijano C., Hernandez-Saavedra D., Castro L., McCord J.M., Freeman B.A., Radi R. Reaction of peroxynitrite with Mn-superoxide dismutase. Role of the metal center in decomposition kinetics and nitration. J Biol Chem 2001, 276:11631-11638.
120. Radi R., Cassina A., Hodara R., Quijano C., Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002, 33:1451-1464.
121. Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 1986, 261:7585-7587.
122. Ramsay R.R., Dadgar J., Trevor A., Singer T.P. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci 1986, 39:581-588.
123. Ransom B.R., Kunis D.M., Irwin I., Langston J.W. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 1987, 75:323-328.
124. Riachi N.J., Harik S.I. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci 1988, 42:2359-2363.
125. Riachi N.J., Dietrich W.D., Harik S.I. Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier. Brain Res 1990, 533:6-14.
126. Riachi N.J., Harik S.I., Kalaria R.N., Sayre L.M. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. JPET 1988, 244:443-448.
127. Riobo N.A., Clementi E., Melani M., Boveris A., Cadenas E., Moncada S., Poderoso J.J. Nitric oxide inhibits mitochondrial NADH: ubiquinone reductase activity through peroxynitrite formation. Biochem J 2001, 359:139-145.
128. Rollema H., Kuhr W.G., Kranenborg G., De Vries J., Van den Berg C. MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. JPET 1988, 245:858-866.
129. Russ H., Staust K., Martel F., Gliese M., Schomig E. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 1996, 8:1256-1264.
130. Saadat S., Stehle A.D., Lamouroux A., Mallet J., Thoenen H. Predicted amino acid sequence of bovine tyrosine hydroxylase and its similarity to tyrosine hydroxylases from other species. J Neurochem 1988, 51:572-578.
131. Schaar D.G., Sieber B.A., Dreyfus C.F., Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 1993, 124:368-371.
132. Schaar D.G., Sieber B.A., Sherwood A.C., Dean D., Mendoza G., Ramakrishnan L., Dreyfus C.F., Black I.B. Multiple astrocyte transcripts encode nigral trophic factors in rat and human. Exp Neurol 1994, 130:387-393.
133. Schabitz W.R., Sommer C., Zoder W., Kiessling M., Schwaninger M., Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 2000, 31:2212-2217.
134. Schipper H.M. Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases. Neurotox Res 1999, 1:57-70.
135. Schipper H.M., Liberman A., Stopa E.G. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 1998, 150:60-68.
136. Schipper H.M., Vininsky R., Brull R., Small L., Brawer J.R. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998, 152:188-196.
137. Schluter O.M., Fornai F., Alessandri M.G., Takamori S., Geppert M., Jahn R., Sudhof T.C. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neurosci 2003, 118:985-1002.
138. Schmidt C.J., Matsuda L.A., Gibb J.W. In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine. Eur J Pharm 1984, 103:255-260.
139. Schmidt J., Mertz K., Morgan J.I. Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes. Mol Brain Res 1999, 73:50-59.
140. Schneider J.S., Denaro F.J. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropath Exp Neurol 1988, 47:452-458.
141. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery, and treatments. Prog Neurobiol 1996, 50:275-331.
142. Scott W.K., Yamaoka L.H., Stajich J.M., Scott B.L., Vance J.M., Roses A.D., Pericak-Vance M.A., Watts R.L., Nance M., Hubble J., Koller W., Stern M.B., Colcher A., Allen F.H., Hiner B.C., Jankovic J., Ondo W., Laing N.G., Mastaglia F., Goetz C., Pappert E., Small G.W., Masterman D., Haines J.L., Davies T.L. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 1999, 2:191-192.
143. Shults C.W. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003, 10:1917-1921.
144. Skaper S.D., Floreani M., Negro A., Facci L., Giusti P. Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J Neurochem 1998, 70:1859-1868.
145. Slivka A., Cohen G. Hydroxyl radical attack on dopamine. J Biol Chem 1985, 260:15466-15472.
146. Smeyne M., Goloubeva O., Smeyne R.J. Strain-dependent susceptibility to MPTP and MPP+-induced Parkinsonism is determined by glia. Glia 2001, 74:73-80.
147. Sonsalla P.K., Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog Neuropsychopharmacol Biol Psychiatry 1988, 12:345-354.
148. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000, 275:18344-18349.
149. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
150. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 1992, 59:99-106.
151. Stoessl A.J. Etiology of Parkinson's disease. Can J Neurol Sci 1999, 26(Suppl 2):S5-S12.
152. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57B1/6 mice. Comparison with three other strains of mice. Brain Res 1987, 405:26-38.
153. Suzuki K., Mizuno Y., Yoshida M. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP_-like compounds on mitochondrial respiration. Adv Neurol 1990, 53:215-218.
154. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A 1997, 94:9938-9943.
155. Teismann P., Tieu K., Cohen O., Choi D.K., Wu du C., Marks D., Vila M., Jackson-Lewis V., Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003, 18:121-129.
156. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003, 100:5473-5478.
157. The Parkinsons Web. http://neurochief.
158. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 2000, 20:9207-9214.
159. Tsukahara T., Takeda M., Shimohama S., Ohara O., Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 1995, 37:733-739.
160. United States Census Bureau Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1993 to 2050 1996.
161. Veldman B.A., Wijn A.M., Knoers N., Praamstra P., Horstink M.W. Genetic and environmental risk factors in Parkinson's disease. Clin Neurol Neurosurg 1998, 100:15-26.
162. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 1995, 95:2458-2464.
163. Wang X.F., Cynader M.S. Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem 2000, 74:1434-1442.
164. Whetten-Goldstein K., Sloan F., Kulas E., Cutson T., Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Ger Soc 1997, 45:479-485.
165. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003, 54:93-101.
166. Wichmann T., DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci 2003, 991:199-213.
167. Williams A.C., Smith M.L., Waring R.H., Ramsden D.B. Idiopathic Parkinson's disease: a genetic and environmental model. Adv Neurol 1999, 80:215-218.
168. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100:6145-6150.
169. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
170. Youdim M.B., Grunblatt E., Levites Y., Maor G., Mandel S. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. Neurotox Res 2002, 4:679-689.
171. Zietlow R., Dunnett S.B., Fawcett J.W. The effect of microglia on embryonic dopaminergic neuronal survival in vitro: diffusible signals from neurons and glia change microglia from neurotoxic to neuroprotective. Eur J Neurosci 1999, 11:1657-1667.